Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial

Trial Profile

Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Atazanavir (Primary) ; Didanosine (Primary) ; Efavirenz (Primary) ; Emtricitabine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/zidovudine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms PEARLS
  • Most Recent Events

    • 01 Sep 2017 Results assessing the association between efavirenz metabolizer genotype and suicidality using pooled data from four clinical trials (A5095, A5142 ,A5175, A5202) published in the Journal of Infectious Diseases.
    • 26 Jul 2017 Results (n=253) of secondary analysis to understand the impact ART drugs on pregnancy and birth outcomes among women from this trial and HPTN 052 and ACTG A5208 trial, were presented at the 9th International AIDS Society Conference on HIV Science.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top